Invesco Dorsey Wright Healthcare Momentum ETF PTH
Set alert
58.36 USD -1.34 -2.24%
As of Nov 2, 12:12 PM ET
57.82 Day range 60.01
46.09 52-week range 64.10
- YTD
- +17.41%
- 1 year
- +19.97%
- Open
- 60.01
- Prev close
- 59.69
- Mkt cap
- 139.39M
- Vol
- 21.79K
- Avg vol
- 39.78K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 57.82
- High
- 60.01
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 44.93
- 200-d avg
- 44.07
1Y chart
Events in this range
- Dec 22, 2025Dividend: 1.52645
Signals (38)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 9 months ago |
| MACD: Buy Signal | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Dec 30, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| RSI: Overbought | Nov 21, 2025 | 11 months ago |
| RSI: Overbought | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 17, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 4, 2025 | 12 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 9.15
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 44.93
- 200-day average
- 44.07
About Invesco Dorsey Wright Healthcare Momentum ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of at least 30 securities of companies in the healthcare sector that have powerful relative strength or "momentum" characteristics.
News
- TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
- Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
- Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?
- Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026
- Moderna Advances Ebola Vaccine Into Human Testing
- Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
- Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?
- Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
- Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
- 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
Your note
Sign in to keep a note on PTH — it syncs with the Stock Master app.